Novartis CEO Vas Narasimhan cuts loose an old anchor and sets sail with $8.7B AveXis buyout
Vas Narasimhan is starting his tenure as CEO of Novartis $NVS with a bold move on the gene therapy front.
The pharma giant has struck …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
